CONCORD, Calif.--(BUSINESS WIRE)--Dec. 6, 2006--Cerus Corporation
(NASDAQ:CERS) today announced that it has entered into agreements with
selected institutional investors for the purchase of up to 3,903,952
shares of its common stock at a purchase price of $6.68 per share. The
net offering proceeds to Cerus are expected to be approximately $24.3
million after deducting placement agency fees and estimated offering
expenses. Banc of America Securities LLC acted as lead placement agent
for the offering and Robert W. Baird & Co. Incorporated acted as
co-placement agent. All of the shares are being offered by Cerus under an effective
shelf registration statement previously filed with the Securities and
Exchange Commission. The shares of common stock may only be offered by
means of a prospectus supplement and accompanying prospectus, a copy
of which may be obtained, when available, from Banc of America
Securities LLC, Capital Markets (Prospectus Fulfillment) by e-mail to
dg.prospectus_distribution@bofasecurities.com or by mail to Banc of
America Securities LLC, Capital Markets Operations, 100 West 33rd
Street, 3rd Floor, New York, NY 10001, or by contacting Robert W.
Baird & Co. Incorporated, 777 East Wisconsin Avenue, 28th Floor,
Milwaukee, WI 53202-5391. This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities. There shall not be any
sale of these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction. ABOUT CERUS Cerus Corporation is a biopharmaceutical company that develops and
commercializes novel, proprietary products in the fields of blood
safety and immunotherapy to provide safer, more effective medical
options to patients in areas of substantial unmet medical needs. In
the field of immunotherapy, the company is employing its proprietary
attenuated Listeria vaccine platform to develop a series of novel
therapies to treat cancer, and it is applying its proprietary Killed
But Metabolically Active technology platform in research and
development of prophylactic and therapeutic vaccines for infectious
diseases. In the field of blood safety, the company is developing and
commercializing the INTERCEPT Blood System, which is based on the
company's proprietary Helinx technology and is designed to enhance the
safety of donated blood components by inactivating viruses, bacteria,
parasites and other pathogens, as well as potentially harmful white
blood cells. INTERCEPT, INTERCEPT Blood System and Helinx are
trademarks of Cerus Corporation. This press release contains forward-looking statements. For this
purpose, any statements contained in this press release that are not
statements of historical fact may be deemed forward-looking
statements, including, without limitation, statements regarding the
company's plans to complete an offering of its securities. Words such
as "estimate," "expect" and similar words or expressions or the
negative of these words or expressions are intended to identify
forward-looking statements. Actual results could differ materially
from these forward-looking statements as a result of certain factors,
including, without limitation, the risk that the offering will not be
completed due to failure to satisfy the closing conditions related to
the offering or other reasons, as well as other risks detailed in the
company's filings with the Securities and Exchange Commission,
including the company's Quarterly Report on Form 10-Q for the fiscal
quarter ended September 30, 2006. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
the date of this press release. The company does not undertake any
obligation to update any forward-looking statements as a result of new
information, future events, changed assumptions or otherwise.
CONTACT: Cerus Corporation
Myesha Edwards, 925-288-6017
Corporate Communications & Investor Relations SOURCE: Cerus Corporation
|